Eli Lilly released the results of the ATTAIN-2 study, in which its orforglipron pill showed efficacy in patients with obesity and type 2 diabetes.[1] The highest dose resulted in an average weight loss of 10.5% over 72 weeks, equivalent to approximately 10 kilograms.[1] In placebo patients, the weight loss was only 2.2%.[1] At the same time, the drug significantly reduced blood sugar levels, with most patients no longer meeting the criteria for type 2 diabetes after the end of the study.[1] The company now has a complete data package to apply for approval to regulators around the world.[1] Eli Lilly plans to launch the drug next year.[1] The study paves the way for global approval of orforglipron.[1]